Member Info for Rocket79

I think some orders will be coming in very soon from UK and other government.

@NovacytGroup #Mpox #Testing

“The first case of Monkeypox virus since 2022 has been tested with the Primer Design Monkeypox qPCR assay in Gauteng, Johannesburg by our customer, Lancet Laboratories

The case was confirmed by the National Institute for Communicable Diseases.

Yes I am in here now. I also missed the covid rise. Could easily see this hit over 1000p if MPOX comes to UK and we start testing.

Monkey Pox. Yes they will be involved again and I don't think very many realise this. All good for profits. Hopefully however we get on top of it for everyone's safety.

Oxford Nanopore were involved on 2022 outbreak. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic

Nothing stopping NOVO buying more that £60 mil. Good luck all

"Oxford Nanopore has made impressive ongoing progress to advance its technology platform and gain commercial traction,” said Daniel Mahony at Novo Growth Investments.

“This investment underscores our belief in Oxford Nanopore’s platform and its expanding opportunity in biopharmaceuticals, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new drug therapies.

“We are confident in Oxford Nanopore’s long-term value proposition after extensive due diligence within the biopharma community and analysis of their robust and extensive IP portfolio.”

250p would be a good start.

They have enough. They just wanted to get Novo on board as an investor.

Smart investors see the value. Buy and hold for substantial gains. This could be the next ARM in terms of creating value for investors. ONT at similar stage in their field.

Only in Ocotber bioMérieux agreed to subscribe for 29,025,326 ordinary shares (which equates to 3.5% of Oxford Nanopore’s voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the “Subscription”), conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly £70 million.

I would think Biomeriux would snap ONT up. They bought at £2.38 only last October.

BioMérieux has agreed to subscribe for 29,025,326 ordinary shares (which equates to 3.5% of Oxford Nanopore’s voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the “Subscription”), conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly £70 million.

200p + ,price target by October 2024 when anti takeover shares expire. BUY

Sounds like preparation for listing in US. That should put a rocket up the share price.

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces the appointment of Berenberg as joint corporate broker alongside Citigroup Global Markets Limited and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) with immediate effect

The Times: The chief executive of Oxford Nanopore has warned that Britain’s most promising companies will be ‘snapped up’ in takeovers or will move their listings to New York unless the new Labour government accelerates financial reforms begun under the Conservatives.

Sequencing for a new generation.

With Apple silicon and Oxford Nanopore, sequencing becomes not just powerful but also more globally accessible...

Https://www.apple.com/uk/healthcare/mac/

Order book on level 2 looking very strong. This will be over 100p by end of week.

Did the directors participate in the placing?

Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine

New workflow to provide unambiguous genetic results in a single assay, alleviating the need for time-consuming and costly follow-up tests

May 22, 2024 05:20 AM Eastern Daylight Time

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.

hxxps://www.businesswire.com/news/home/20240522912932/en/Oxford-Nanopore-Technologies-Collaborates-With-Twist-Bioscience-to-Launch-Pharmacogenomics-Beta-Programme-and-Advance-Personalised-Medicine/

160p first resistance... this is going to rerate. Hood news coming from the US on inflation.